#1 Clinical Trials Search in Europe

Ropivacaine Hydrochloride Monohydrate

This article explores the use of Ropivacaine Hydrochloride Monohydrate in clinical trials, specifically focusing on its application in treating acute lower back pain. The drug is being studied as part of an anesthetic block for the erector spinae muscles to provide relief from recent lumbago. This low-interventional trial aims to validate the efficacy of this treatment approach and assess various aspects of pain management and patient recovery.

Table of Contents

What is Ropivacaine Hydrochloride Monohydrate?

Ropivacaine Hydrochloride Monohydrate is the active ingredient in a medication called Ropivacaine Noridem. It belongs to a class of drugs known as local anesthetics, specifically amide-type local anesthetics. This medication is used to provide pain relief in certain medical procedures and conditions[1].

Medical Use: Treating Acute Lower Back Pain

Ropivacaine is being studied for its effectiveness in treating acute lower back pain, also known as lumbago. This condition refers to sudden and severe pain in the lower back that typically lasts for a short period, usually less than seven days[1].

In a clinical trial, researchers are investigating the use of ropivacaine in an anesthetic block of the erector spinae muscles. These are the muscles that run along your spine and help you stand up straight. The main goal is to see if this treatment can effectively relieve pain from muscle contractures (tight, painful muscles) during a recent bout of lumbago[1].

How Ropivacaine Works

Ropivacaine works by temporarily numbing the area where it’s injected. It does this by blocking the nerve signals that transmit pain sensations to the brain. In the case of lower back pain, when injected near the erector spinae muscles, it can help reduce pain and muscle tension in the affected area[1].

How Ropivacaine is Administered

Ropivacaine Noridem is available as a solution for injection. The concentration used in the study is 7.5 mg/mL. It is administered by a healthcare professional through an injection near the affected area in the lower back. The maximum daily dose in the study is 2 mL, which is equivalent to 15 mg of ropivacaine[1].

Effectiveness of Ropivacaine

The effectiveness of ropivacaine for acute lower back pain is being evaluated in the clinical trial. Researchers are measuring several factors to determine its efficacy:

  • Pain levels at rest and during activity over the first 4 days after treatment
  • Pain levels at day 4 following the anesthetic block
  • The percentage of patients with pain levels below 3 (on a numeric scale) at rest on day 4
  • Functional improvement using the OSWESTRY index, which measures how lower back pain affects a person’s everyday life
  • The duration of interruption to normal and professional activities up to 28 days after treatment

These measurements will help determine how well ropivacaine works for relieving acute lower back pain[1].

Who is Eligible for Ropivacaine Treatment?

Based on the clinical trial criteria, patients who might be eligible for this treatment include:

  • Those with lumbago lasting less than 7 days despite using pain relievers or anti-inflammatory drugs
  • Patients with pain levels greater than 6 on a numeric scale
  • Those with an Oswestry score (a measure of low back disability) of 30 or higher

However, certain conditions may make a person ineligible for this treatment. These include pregnancy, breastfeeding, certain medical conditions, and use of specific medications[1].

Potential Side Effects and Complications

As with any medical treatment, ropivacaine may cause side effects. The clinical trial is monitoring for several potential complications, including:

  1. Injection-site related: hematoma (bruising), nerve damage, limb pain
  2. Systemic reactions: convulsions, respiratory discomfort, slow heart rate (bradycardia), severe vagal malaise (feeling faint)
  3. Accidental events: falls, infections
  4. Back-related issues: new lumbago, sciatica, or complicated crural neuralgia (leg pain with neurological symptoms)
  5. Other: allergic reactions, digestive or kidney complications

It’s important to note that not all patients will experience these side effects, and the likelihood of serious complications is generally low[1].

Precautions and Contraindications

Ropivacaine may not be suitable for everyone. The clinical trial excludes patients with certain conditions or characteristics, including:

  • Presence of “red flag” symptoms suggesting more serious conditions (e.g., motor deficits, signs of cauda equina syndrome, nighttime pain, cancer, infection, osteoporosis)
  • Pregnancy or breastfeeding
  • Use of certain blood thinners
  • Known hypersensitivity to ropivacaine or its ingredients
  • Chronic respiratory insufficiency or cardiac rhythm disorders
  • Poor local skin condition at the injection site

Always inform your healthcare provider about all your medical conditions and medications before starting any new treatment[1].

Aspect Details
Drug Name Ropivacaine Hydrochloride Monohydrate
Trial Category Low interventional trial
Medical Condition Acute lower back pain (lumbago)
Main Objective Validate efficacy of anesthetic blocks on erector spinae muscles for pain relief
Primary Endpoint Area under the curve of pain scores during activity over first 4 days
Key Inclusion Criteria Lumbago <7 days, pain score >6, Oswestry score ≥30
Key Exclusion Criteria “Red flag” symptoms, pregnancy, infection risk, hypersensitivity to Ropivacaine
Secondary Objectives Evaluate analgesic consumption, pain at rest and in activity, functional improvement, complications
Drug Administration Injectable solution, maximum daily dose 2 ml
Follow-up Period Up to 28 days

FAQ

  • What is the main objective of this clinical trial using Ropivacaine Hydrochloride Monohydrate? The main objective is to validate the effectiveness of anesthetic blocks of the erector spinae muscles, using Ropivacaine Hydrochloride Monohydrate, in relieving pain from muscle contractures during recent lumbago over the first 4 days of treatment.
  • Who is eligible to participate in this clinical trial? Eligible participants include patients with lumbago lasting less than 7 days despite analgesic/NSAID treatment, those with pain levels greater than 6 on a numeric scale, and an Oswestry score of 30 or higher. Participants must be willing to comply with the trial protocol and be affiliated with social security or health insurance.
  • What are some of the exclusion criteria for this trial? Exclusion criteria include the presence of 'red flag' symptoms (such as motor deficit or signs of cauda equina syndrome), pregnancy or breastfeeding, participation in other clinical research protocols, inability to follow the protocol, risk of infection, poor local skin condition, and hypersensitivity to Ropivacaine or its excipients.
  • How is the effectiveness of the treatment being measured? The primary measure of effectiveness is the area under the curve of pain scores (using a numeric scale) during activity over the first 4 days of treatment. Secondary measures include pain at rest, pain during activity, functional improvement using the Oswestry index, and the number of days off work.
  • What potential complications are being monitored in this trial? The trial is monitoring for complications such as injection-site hematoma, nerve damage, respiratory discomfort, bradycardia, falls, iatrogenic infections, new lumbago or sciatica, allergic reactions, and digestive or renal complications.

Ongoing Clinical Trials on Ropivacaine Hydrochloride Monohydrate

  • Study of Ropivacaine and Dexamethasone Injection for Acute Low Back Pain Relief: Testing the Effectiveness of Erector Spinae Muscle Block

    Recruiting

    1 1 1
    Investigated drugs:
    France

Glossary

  • Lumbago: Lumbago is another term for lower back pain, typically characterized by muscle tension or stiffness in the lower back area.
  • Erector spinae muscles: These are a group of muscles that run along the length of the spine, helping to straighten the back and rotate the trunk.
  • Anesthetic block: A medical procedure where an anesthetic is injected near nerves to numb a specific area of the body, in this case, the lower back muscles.
  • Ropivacaine Hydrochloride Monohydrate: A local anesthetic drug used to numb an area of the body during and after surgery or other medical procedures.
  • NSAIDs: Non-Steroidal Anti-Inflammatory Drugs, a class of medications used to reduce pain, fever, and inflammation.
  • Oswestry score: A tool used to measure the degree of disability in people with low back pain, also known as the Oswestry Disability Index.
  • Numeric Scale (NS) pain: A method of rating pain intensity on a scale from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable.
  • Area under the curve: A statistical method used to analyze pain scores over time, providing a comprehensive view of pain levels throughout the study period.
  • Cauda equina syndrome: A serious neurological condition affecting the bundle of nerve roots at the lower end of the spinal cord, which can cause loss of function in the lower body.
  • Iatrogenic: Referring to a condition or complication inadvertently caused by medical treatment or diagnostic procedures.

References

  1. http://clinicaltrials.eu/trial/study-on-dexamethasone-phosphate-and-ropivacaine-hydrochloride-for-acute-lower-back-pain-relief-in-patients-with-recent-lumbago/